Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
- Conditions
- PainProstate CancerQuality of Life
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 227
- Registration Number
- NCT00003232
- Locations
- 🇨🇦
Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor, Ontario, Canada
🇨🇦Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
- Conditions
- Metastatic CancerPain
- Interventions
- Radiation: radiation therapy
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 850
- Registration Number
- NCT00080912
- Locations
- 🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦The Vitalite Health Network - Dr. Leon Richard, Moncton, New Brunswick, Canada
🇨🇦Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Lung CancerUnspecified Adult Solid Tumor, Protocol SpecificHead and Neck CancerOvarian Cancer
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 14
- Registration Number
- NCT00006036
- Locations
- 🇨🇦
Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximab
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 849
- Registration Number
- NCT00078949
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 34
- Registration Number
- NCT00079079
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 19
- Registration Number
- NCT00079053
- Locations
- 🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Canada
🇨🇦London Regional Cancer Program, London, Canada
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
- Conditions
- Colorectal CancerQuality of Life
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 572
- Registration Number
- NCT00079066
- Locations
- 🇨🇦
Hopital Charles Lemoyne, Greenfield Park, Quebec, Canada
🇨🇦Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada
🇨🇦Hopital Du Sacre-Coeur de Montreal, Montreal, Quebec, Canada
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 67
- Registration Number
- NCT00006890
- Locations
- 🇺🇸
St. Mary's/Duluth Clinic Health System, Duluth, Minnesota, United States
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦Moncton Hospital, Moncton, New Brunswick, Canada
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Cavity Cancer
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 81
- Registration Number
- NCT00010179
- Locations
- 🇨🇦
Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
🇨🇦BCCC - Cancer Center for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 555
- Registration Number
- NCT00003011
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada